EPISODE · Sep 20, 2018 · 33 MIN
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
from Plenary Session - inactive due to federal service · host Vinay Prasad, MD MPH
Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.
Embed this episode
NOW PLAYING
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
0:00
33:41
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Plenary Session - inactive due to federal service?
This episode is 33 minutes long.
When was this Plenary Session - inactive due to federal service episode published?
This episode was published on September 20, 2018.
Can I download this Plenary Session - inactive due to federal service episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!